Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20)

被引:31
作者
Erdmann, Erland [1 ]
Spanheimer, Robert [2 ]
Charbonnel, Bernard [3 ]
机构
[1] Univ Cologne, Med Klin 3, D-50937 Cologne, Germany
[2] Takeda Pharmaceut N Amer, Deerfield, IL USA
[3] Hop Hotel Dieu, Clin Endocrinol, Nantes 1, France
关键词
diabetes complications; pioglitazone; polypharmacy; Type; 2; diabetes; CONGESTIVE-HEART-FAILURE; MYOCARDIAL-INFARCTION; CLINICAL-TRIAL; ROSIGLITAZONE; METAANALYSIS; THIAZOLIDINEDIONES; ASSOCIATION; MELLITUS; OUTCOMES; DEATH;
D O I
10.1111/j.1753-0407.2010.00082.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Patients with Type 2 diabetes mellitus (T2DM) are often treated with multiple glucose-lowering and cardiovascular agents. The concomitant use of nitrates, renin-angiotensin system (RAS) blockers, or insulin has been linked to a potential increase in myocardial ischemic risk with rosiglitazone. The PROactive database provides an opportunity to investigate the effects of these medications on the potential macrovascular benefits reported with pioglitazone. Methods: The PROactive study was a randomized double-blind prospective trial that evaluated mortality and cardiovascular morbidity in 5238 patients with T2DM and macrovascular disease. Patients received pioglitazone or placebo in addition to their baseline glucose-lowering and cardiovascular medications. The effect of pioglitazone on composite endpoints was evaluated, including all-cause death, myocardial infarction (MI), and stroke, as well as safety events of edema and serious heart failure, in subgroups using nitrates, RAS blockers, or insulin at baseline. Results: The risk of all-cause death, MI, and stroke for pioglitazone versus placebo was similar regardless of the baseline use of nitrates, RAS blockers, or insulin, with hazard ratios ranging from 0.81 to 0.87. Similar results were obtained for the other composite endpoints analyzed. There were no significant interactions between baseline medication subgroups and treatment. The increased risk of edema and serious heart failure was consistent across the baseline medication subgroups. Conclusions: This post hoc analysis did not reveal an increased risk of macrovascular events with pioglitazone in patients receiving nitrates, RAS blockers, or insulin. Rather, all patients realized the same trend towards benefit with pioglitazone, and adverse events of edema and heart failure were predictable.
引用
收藏
页码:212 / 220
页数:9
相关论文
共 41 条
  • [1] [Anonymous], 1999, Diabet Med, V16, P716
  • [2] [Anonymous], 2007, LANCET, V369, P1834, DOI [10.1056/NEJMoao66224, 10.1016/S0140-6736(07)60787-9]
  • [3] [Anonymous], JOINT M END MET DRUG
  • [4] Austin R.P., 2006, Diabetes Spectrum, V19, P13, DOI DOI 10.2337/DIASPECT.19.1.13
  • [5] Thiazolidinediones and the risk of edema: A meta-analysis
    Berlie, Helen D.
    Kalus, James S.
    Jaber, Linda A.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2007, 76 (02) : 279 - 289
  • [6] PROactive: time for a critical appraisal
    Betteridge, D. John
    DeFronzo, Ralph A.
    Chilton, Robert J.
    [J]. EUROPEAN HEART JOURNAL, 2008, 29 (08) : 969 - 983
  • [7] Rosiglitazone and myocardial infarction: cause for concern or misleading meta-analysis?
    Bilous, R. W.
    [J]. DIABETIC MEDICINE, 2007, 24 (09) : 931 - 933
  • [8] Bracken MB, 2007, NEW ENGL J MED, V357, P937
  • [9] Misleading meta-analysis: a need to look beyond the headlines
    Chaturvedi, N.
    Bilous, R.
    Hardy, R.
    Remuzzi, G.
    Ruggenenti, P.
    Viberti, G. C.
    [J]. DIABETIC MEDICINE, 2007, 24 (06) : 587 - 591
  • [10] A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14 237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone
    Cobitz, Alexander
    Zambanini, Andrew
    Sowell, Margaret
    Heise, Mark
    Louridas, Bonnie
    McMorn, Stephen
    Semigran, Marc
    Koch, Gary
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 (08) : 769 - 781